scholarly journals The impact of antibody selection on the detection of cardiac troponin I

2013 ◽  
Vol 420 ◽  
pp. 82-88 ◽  
Author(s):  
Moltu J. Guy ◽  
Yi-Chen Chen ◽  
Laura Clinton ◽  
Han Zhang ◽  
Jiang Zhang ◽  
...  
Keyword(s):  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
The Impact

scholarly journals The impact of hepatitis B carrier on cardiac troponin I in 100-km ultramarathon runners

2017 ◽  
Vol 80 (6) ◽  
pp. 347-352 ◽  
Author(s):  
Li-Hua Li ◽  
Chorng-Kuang How ◽  
Wei-Fong Kao ◽  
Yu-Hui Chiu ◽  
Chen Meng ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
The Impact ◽  
Hepatitis B Carrier

scholarly journals Cardiac troponin I and the risk of cardiovascular or non-cardiovascular death in patients visiting the emergency department

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jong Eun Park ◽  
Minseok Song ◽  
Taerim Kim ◽  
Gun Tak Lee ◽  
Sung Yeon Hwang ◽  
...  
Keyword(s):  
Emergency Department ◽  
Risk Analysis ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiovascular Death ◽  
Cardiac Troponin I ◽  
Emergency Department Visits ◽  
Time Dependent ◽  
Increased Risk ◽  
The Impact

AbstractThe prognostic implication of cardiac troponin I (cTnI) values for the determination of the magnitude or duration of cause-specific death risk is limited. We included consecutive patients with maximal cTnI values within 24 h of their emergency department visits. Multivariate analyses using variables selected by the Bayesian information criterion were performed to investigate the impact of cTnI on the event rate, time-dependent risk, and dose-dependent risk of cardiovascular or non-cardiovascular death within 360 days. There were 5472 (14.9%) all-cause deaths including 881 (2.4%) cardiovascular deaths and 4591 (12.5%) non-cardiovascular deaths. In patients with positive cTnI, defined as the ≥ 99th percentile of the upper normal limit, the cumulative risk of cardiac and non-cardiac death was 4.4- and 1.4-fold higher, respectively, than that of negative cTnI, respectively. In the competing risk analysis, positive cTnI was linked to 2.4- and 1.2-fold higher risks of cardiovascular and non-cardiovascular death, respectively. The cTnI value showed a positive relationship with the risk of both cardiovascular and non-cardiovascular deaths. In the time-dependent risk analysis, the excess risk of cardiovascular death was mostly evident in the first few weeks. Higher cTnI value was associated with an increased risk of both cardiovascular and non-cardiovascular death, especially which was in the early period.

The impact of exercise intensity on cardiac troponin I release

2014 ◽  
Vol 171 (1) ◽  
pp. e3-e4 ◽  
Author(s):  
Thijs M.H. Eijsvogels ◽  
Maurits D. Hoogerwerf ◽  
Madelijn H. Oudegeest-Sander ◽  
Maria T.E. Hopman ◽  
Dick H.J. Thijssen
Keyword(s):  
Exercise Intensity ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
The Impact

scholarly journals Clinical and Analytical Performance of the Liaison Cardiac Troponin I Assay in Unstable Coronary Artery Disease, and the Impact of Age on the Definition of Reference Limits. A FRISC-II Substudy

2003 ◽  
Vol 49 (6) ◽  
pp. 880-886 ◽  
Author(s):  
Per Venge ◽  
Nina Johnston ◽  
Bo Lagerqvist ◽  
Lars Wallentin ◽  
Bertil Lindahl ◽  
...  
Keyword(s):  
Cardiac Troponin ◽  
First Generation ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Analytical Performance ◽  
Cardiac Events ◽  
Unstable Coronary Artery Disease ◽  
Age Related ◽  
The Impact ◽  
Cardiac Troponins

Abstract Background: Measurements of cardiac troponins are currently used as the standard for the detection of myocardial injury. None of the current assays complies with the new requirements on assay imprecision as proposed by the European Society of Cardiology/American College of Cardiology. Our aim was to evaluate the clinical and analytical performance of the Liaison cardiac troponin I (cTnI) assay. Methods:EDTA-plasma was used, and cardiac troponins were assayed with the first-generation AxSYM assay, the second-generation AccuTnI assay, the third-generation Elecsys assay, and the first-generation Liaison assay. Results: In a 6-day imprecision study, the Liaison cTnI assay had mean CV ≤10% at 0.027 μg/L and ≤20% at 0.015 μg/L. The 99th percentile of the upper reference limit (URL) of a reference population was 0.041 μg/L (age range, 41–76 years). Individuals <60 years had a significantly (P = 0.001) lower 99th percentile, 0.022 μg/L. The FRISC-II study participants with cTnI ≥0.041 μg/L had a poorer outcome relating to death/acute myocardial infarction than those with cTnI <0.041 μg/L (P <0.001). Treatment with low-molecular-weight heparin (dalteparin) or an invasive strategy reduced cardiac events only in patients with concentrations >0.041 μg/L (P = 0.002 and 0.02, respectively). Comparison with the AccuTnI assay showed that a large cohort of the patients with poor prognosis was identified by the AccuTnI assay but not by the Liaison cTnI assay. Conclusion: The Liaison cTnI assay is a sensitive assay with a CV ≤10% at the 99th percentile URL. The ability to detect age-related differences among apparently healthy individuals is unique among today’s commercial assays. The results indicate that different assays seem to identify different patient cohorts for cardiac risk in the lower range of cTnI concentrations.

Sign in / Sign up

Export Citation Format

Share Document